Monitoring of the anticoagulants argatroban and lepirudin: A comparison of laboratory methods

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 5, 2011, Pages 549-555

  Ivandic, Boris ^a,b   Zorn, Markus ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b SYNLAB ACADEMY   (Germany)

Author keywords

anticoagulants; in vitro diagnostic systems; thrombosis prophylaxis

Indexed keywords

ARGATROBAN; ECARIN; LEPIRUDIN;

ANTICOAGULANT THERAPY; ARTICLE; AUTOMATION; BLOOD CLOTTING TIME; CLINICAL ARTICLE; DRUG MONITORING; DRUG SAFETY; HUMAN; INTENSIVE CARE; OUTPATIENT; PRIORITY JOURNAL; THROMBIN TIME; THROMBOPLASTIN TIME;

ANTITHROMBINS; CALIBRATION; FEMALE; HIRUDINS; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBIN TIME;

EID: 80053582982     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610382651     Document Type: Article

References (12)

1. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003 ; 163 (15). 1849-1856 (Pubitemid 36960936)
2. Levin RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest. 2006 ; 129 (5). 1167-1175
3. Hursting MJ, Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf. 2009 ; 32 (3). 203-218
4. Berry C, Girandot C, Lecroffre C, Lunven C. Effect of synthetic thrombin inhibitor argatroban on fibrin- and clot-incorporated thrombin: a comparison with heparin and recombinant hirudin. Thromb Haemost. 1994 ; 72 (3). 381-386 (Pubitemid 24280776)
5. Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004 ; 66 (6). 2446-2453
6. Link A, Girndt M, Selejans S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009 ; 37 (1). 1-6
7. Walenga J, Ahmad S, Hoppenstedt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res. 2002 ; 105 (5). 401-405 (Pubitemid 34621257)
8. Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis. 2005 ; 16 (4). 251-257 (Pubitemid 40705046)
9. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004 ; 38 (9). 1383-1388 (Pubitemid 39100188)
10. Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res. 1997 ; 86 (5). 373-383 (Pubitemid 27305589)
11. Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost. 2002 ; 28 (4). 361-368 (Pubitemid 34971923)
12. Beiderlinden M, Treschan TA, Görlinger K, Peters J. Argatroban Anticoagulation in criticallay ill patients. Ann Pharmacother. 2007 ; 41 (5). 749-53